BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2024. Filed Feb 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 24, 2025
BMRN$57.13-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
(In thousands of U.S. Dollars, except per share amounts)
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| REVENUES: | |||
| Net product revenues | $2,809,445 | $2,372,538 | $2,042,025 |
| Royalty and other revenues | 44,470 | 46,688 | 54,014 |
| Total revenues | 2,853,915 | 2,419,226 | 2,096,039 |
| OPERATING EXPENSES: | |||
| Cost of sales | 580,235 | 532,062 | 503,023 |
| Research and development | 747,184 | 746,773 | 649,606 |
| Selling, general and administrative | 1,009,025 | 892,406 | 823,243 |
| Intangible asset amortization | 43,257 | 62,211 | 67,193 |
| Gain on sale of nonfinancial assets | (10,000) | — | (108,000) |
| Total operating expenses | 2,369,701 | 2,233,452 | 1,935,065 |
| INCOME FROM OPERATIONS | 484,214 | 185,774 | 160,974 |
| Interest income | 74,883 | 58,339 | 18,034 |
| Interest expense | (12,666) | (17,335) | (15,970) |
| Other expense, net | (4,668) | (38,215) | (13,462) |
| INCOME BEFORE INCOME TAXES | 541,763 | 188,563 | 149,576 |
| Provision for income taxes | 114,904 | 20,918 | 8,015 |
| NET INCOME | $426,859 | $167,645 | $141,561 |
| EARNINGS PER SHARE, BASIC | $2.25 | $0.89 | $0.76 |
| EARNINGS PER SHARE, DILUTED | $2.21 | $0.87 | $0.75 |
| Weighted average common shares outstanding, basic | 190,027 | 187,834 | 185,266 |
| Weighted average common shares outstanding, diluted | 196,708 | 191,595 | 188,963 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.